- Home
- CWK vs VKTX Comparison
CWK vs VKTX Comparison
Compare CWK & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CWK | VKTX |
|---|---|---|
| Founded | 1784 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.3B |
| IPO Year | 2018 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CWK | VKTX |
|---|---|---|
| Price | $13.97 | $28.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | $18.07 | ★ $87.07 |
| AVG Volume (30 Days) | 1.6M | ★ 3.2M |
| Earning Date | 02-19-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 152.30 | N/A |
| EPS | ★ 0.95 | N/A |
| Revenue | ★ $10,003,900,000.00 | N/A |
| Revenue This Year | $8.73 | N/A |
| Revenue Next Year | $2.34 | N/A |
| P/E Ratio | $17.12 | ★ N/A |
| Revenue Growth | ★ 6.77 | N/A |
| 52 Week Low | $7.64 | $18.92 |
| 52 Week High | $17.40 | $43.15 |
Technical Indicators
Market Signals| Indicator | CWK | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 33.31 | 40.07 |
| Support Level | $14.92 | $25.77 |
| Resistance Level | $16.64 | $29.70 |
| Average True Range (ATR) | 0.76 | 1.64 |
| MACD | -0.15 | -0.10 |
| Stochastic Oscillator | 12.56 | 30.21 |
Price Performance
Historical ComparisonAbout CWK Cushman & Wakefield plc
Cushman & Wakefield is one of the largest commercial real estate services firms in the world, with global headquarters in Chicago. The firm provides various real estate-related services to owners, occupiers, and investors. These include brokerage services for leasing and capital markets sales as well as advisory services such as valuation, project management, and facilities management.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.